Effect of Calcitriol combined with Olmesartan Medoxomil in the treatment of early type 2 diabetes nephropathy and its mechanism on nephrotic podocyte damage
1.Department of Nephrology, Wuhu Second People’s Hospital, Anhui Province, Wuhu 241000, China;
2.Department of Nephrology, the First Affiliated Hospital of Nanjing Medical University Jiangsu Provincial People’s Hospital, Jiangsu Province, Nanjing 210029, China
Abstract：Objective To investigate the effect of Calcitriol combined with Olmesartan Medoxomil in treatment of early type 2 diabetic nephropathy (T2DN) and the mechanism of nephrotic podocyte damage. Methods A total of 82 early T2DN patients admitted to Wuhu Second People’s Hospital of Anhui Province from January 2018 to December 2019 were selected as the research objects, and they were divided into study group and control group by random number table method, with 41 cases in each group. The control group was treated with Olmesartan Medoxomil on the basis of conventional treatment, and the study group was treated with Calcitriol on the basis of the control group. The clinical efficacy and safety of the two groups were compared, and the levels of microRNA-30 (miR-30) and serum creatinine (Scr) of the two groups were compared before treatment (T0), at week 1 (T1), week 4 (T2) and week 8 (T3) after treatment. Results The curative effect of the study group was better than that of the control group (P ＜ 0.05). The overall analysis found that: the comparison of Scr, miR-30 between groups, time points, and interaction were statistically significant (P ＜ 0.05). Further pairwise comparison, intra-group comparison: at T1, T2, and T3, the levels of Scr and miR-30 in the two groups were lower than those at T0 (P ＜ 0.05). At T2 and T3, the levels of Scr and miR-30 in the two groups were lower than those at T1 (P ＜ 0.05). At T3, the levels of Scr and miR-30 in the two groups were lower than at T2 (P ＜ 0.05). Comparison between groups: At T1, T2, and T3, the levels of Scr and miR-30 in the study group were lower than those in the control group (P ＜ 0.05). During the treatment period, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Calcitriol combined with Olmesartan Medoxomil has a significant effect in the treatment of early T2DN and improves renal podocyte damage. The mechanism may be related to the inhibition of podocyte damage in miR-30 patients.
黄程1 邵云侠1 吴艳1 邢昌赢2▲. 骨化三醇联合奥美沙坦酯治疗早期2型糖尿病肾病的效果及对肾病足细胞损伤的机制探讨[J]. 中国医药导报, 2022, 19(15): 79-82.
HUANG Cheng1 SHAO Yunxia1 WU Yan1 XING Changying2▲. Effect of Calcitriol combined with Olmesartan Medoxomil in the treatment of early type 2 diabetes nephropathy and its mechanism on nephrotic podocyte damage. 中国医药导报, 2022, 19(15): 79-82.
京公网安备 11010502046598号